32
Confidential

Slideshow Version

  • Upload
    prezi22

  • View
    136

  • Download
    1

Embed Size (px)

Citation preview

Page 1: Slideshow Version

Confidential

Page 2: Slideshow Version

3633 Central Avenue, Ste. I • Hot Springs, AR 71913 Phone: (501) 542-4052 • Fax: (501) 321-2886

E-mail: [email protected] • Website: www.burkepharmaceutical.com

Confidential

Page 3: Slideshow Version

Statements under the Private Securities Litigation Reform Act: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to enter into partnering agreements or raise financing on acceptable terms, successful completion of clinical development programs, regulatory review and approval, product development and acceptance, manufacturing, competition, and/or other factors, some of which are outside the control of the Company.

Confidential

Page 4: Slideshow Version

o To develop innovative dermatology products for unmet medical needs:

• Develop new indications for approved drugs• Develop New Delivery Systems • Develop improved formulations • Rx or OTC (NDA, ANDA, monograph products)• Employ 505(b)(2) NDA regulatory strategy

Confidential

Page 5: Slideshow Version

Burke Pharmaceuticals, Inc. is dedicated to delivering innovative dermatology products. Novel delivery systems, superior formulations and strategic planning by an experienced team are priority. Convenient products will address unmet medical needs for both patients and physicians.

Confidential

Page 6: Slideshow Version

Confidential

Page 7: Slideshow Version

Confidential

Management Team

Page 8: Slideshow Version

Dowling B. Stough M.D., F.A.A.D., C.C.T.I.• Dr. Stough is the founder and practicing dermatologist of The Dermatology Clinic, P.A. and medical director of Burke

Pharmaceutical Research. Founded in 2000, Burke Pharmaceutical has grown from a small clinical trials unit within a dermatology practice to a national leader in clinical trials of skin disease. Currently, it employs an experienced site manager, three clinical coordinators, a full time advanced nurse practitioner and three physician investigators. Over the last 10 years, Burke Pharmaceutical Research has been involved in over ninety clinical studies. Dr. Stough has served as the medical director for various pharmaceutical companies conducting clinical trials, and has conducted multiple investigator-initiated studies.

• Dr. Stough holds patents on a medical device known as the “Wart Eraser.” He has also been instrumental in developing other medical devices.

• Dr. Stough is the founder and past president of the International Society of Hair Restoration Surgery. He was the author of two leading textbooks dedicated to hair restoration surgery. He has written over 50 scientific publications and has contributed numerous textbook chapters. He has presented over 180 medical lectures at scientific meetings and was the recipient of the “Golden Follicle Award” by the International Society of Hair Restoration Surgery. He is a fellow of the American Academy of Dermatology and holds a certified physician investigator designation from the Association of Clinical Research Professionals. His interest in dermatologic drug development is preceded by over 15 years of hands on exposure to clinical trials and protocol development.

Confidential

Page 9: Slideshow Version

Dowling B. Stough M.D., F.A.A.D., C.C.T.I. Dr. Stough has always had an interest in research, after his medicine internship at Baptist Hospital in

Memphis, Tennessee; he was involved in research during his dermatology residency at the University of Arkansas Medical School. Following this, Dr. Stough was accepted into a one year fellowship sponsored by the American Academy of Cosmetic Surgery. After maintaining an active dermatology practice for 20 years, he recently divested his practice to devote full time attention to clinical research and drug development. He continues as Clinical Assistant Professor of Dermatology at the University of Arkansas for Medical Sciences. He maintains active licenses in Arkansas, Florida, Texas, Tennessee, and New York and continues to see research related patients.

BURKE Pharmaceutical is dedicated to the commercial development of pharmaceutical products and will draw upon the experience and knowledge gained thru years of research and medical practice. The targeted products will be physician driven and will fill voids that have not been currently addressed by other pharmaceutical companies.

Confidential

Page 10: Slideshow Version

Tim Dugan, BS, CCRC Mr. Dugan has over 11 years of experience in clinical research. He has developed a large database of

contacts with key personnel in the industry. Seven years ago, he became the director of clinical operations for Burke Pharmaceutical Research. As director, Mr. Dugan handles all the clinical and regulatory aspects involved in the trial studies; oversees all assisting personnel, negotiates contracts and budgets, and supervises subject conduct during the trial. He is also instrumental in feasibility studies in the early development of proprietary drugs initiated by BLU Pharmaceutical.

After graduation from the University of Arkansas, he began his career in clinical trial research at Physicians Group Research Clinic. While employed, he successfully attained his certificate as a Certified Clinical Research Coordinator. He then became the regional director of Clinical Operations for Research Solutions, a national site management organization based in Little Rock, Arkansas. He served as the director overseeing 10 clinical research sites and managed a dozen research coordinators.

Mr. Dugan received a B.S. in Biology from the University of Arkansas. He also holds certifications from the

Association of Clinical Research Professionals, Certified Clinical Research Coordinator (CCRC), Model Agreement Group Initiative, and Clinical Research Contract Professional (CRCP).

Confidential

Page 11: Slideshow Version

William R. Pfister, Ph.D. Ph.D. in Pharmacology and Toxicology.

Senior level executive with 30 years of pharmaceutical company experience in: quality control, technical service, product development, preclinical and clinical affairs, regulatory affairs & quality assurance, project management, scientific affairs and business development.

Held senior management positions and supported pharmaceutical product research and development at Hoffmann La-Roche, American Critical Care, Dow Corning Corporation, PharMetrix Corporation, Lavipharm Laboratories, NexMed USA, NAL Pharmaceuticals and BLU Pharmaceuticals, Inc.

Expertise in topical, transdermal, parenteral products and controlled release systems. Developed regulatory strategy and authored and filed numerous INDs and amendments (CMC, preclinical and clinical), NDAs and eCTDs.

Certified Regulatory Affairs Professional (RAC), Diplomate of the American Board of Toxicology (DABT), and is author of several patents, publications and books including: “Transdermal and Topical Drug Delivery Systems, (1997) and “Intraoral Drug Delivery: Molecules to Market” (2005).

Confidential

Page 12: Slideshow Version

Confidential

Page 13: Slideshow Version

2. Improved OTC Dermatology Products:

1. Novel Rx Dermatology Products:

Confidential

Page 14: Slideshow Version

Confidential

Page 15: Slideshow Version

Confidential

Page 16: Slideshow Version

Confidential

Page 17: Slideshow Version

Confidential

Patent Portfolio: 2 patents & 3 Applications

1. Stough, DB, Wart Removal Method and Device, US Patent Application No. US

002/0169462A1, published November 14, 2004.2. Stough, DB, Wart Removal Method and Device,

US Patent 6,585,742,B2, issued July 1, 2003.3. Stough, DB, Wart Removal Method and Device,

US Patent Application No. US 004/0138679A1, published July 15, 2004.4. Stough, DB, Wart Removal Method and Device,

US Patent 7,056,324,B2, issued June 6, 2006.5. Stough, DB, Wart Removal method and Device,

US Patent Application No. US 2006/0200174 A1, published September 7, 2006.

Wart Eraser

Page 18: Slideshow Version

Confidential

Page 19: Slideshow Version

Confidential

Page 20: Slideshow Version

Confidential

Source:  Jean Bologania 2nd edition Dermatology pg. 1183.

Page 21: Slideshow Version

An analysis which factors efficiency into the cited percent response rates determined the cost of the varying wart treatments as follows:

Interferon Alpha $ 1,681 Liquid Nitrogen $ 1,248 Squaric Acid $ 982 Pulsed-dye Laser $ 690 Bleomycin $ 669 Candida Antigen $ 381 Carbon Dioxide Laser $ 356

Source: Comparing Therapy Costs for Physician Treatment of Warts, Journal of Drugs in Dermatology, Dec 2003, Robert J Clemons, Annette Clemons-Miller, Sandra Marchese Johnson, Susan K Williamson, Thomas D Horn.

Confidential

Page 22: Slideshow Version

Percent Market Share

Confidential

Page 23: Slideshow Version

Confidential

Page 24: Slideshow Version

Confidential

Page 25: Slideshow Version

Confidential

Page 26: Slideshow Version

Confidential

Page 27: Slideshow Version

Confidential

Page 28: Slideshow Version

Confidential

Page 29: Slideshow Version

Confidential

Page 30: Slideshow Version

Confidential

Page 31: Slideshow Version

Confidential

Page 32: Slideshow Version

Thank You for Your Attention!